不可切除III期非小细胞肺癌4Gy大分割调强放疗的生存与毒性
这项回顾性研究分析了42例不可切除III期非小细胞肺癌患者,接受铂类双药诱导化疗后约60Gy/15次(4Gy/次)大分割调强放疗。中位随访46个月,中位总生存47个月,5年总生存率32%,但≥3级肺毒性和食管毒性需关注。
要点
- 4Gy×15次大分割调强放疗后中位总生存47个月,5年生存率32%。
- 孤立性局部区域复发率12%,≥3级肺毒性14%,G5肺毒性4.8%。
- G3放射性食管炎12%,G4食管毒性2%,需前瞻性研究验证。
核心结论
- 不可切除局部晚期非小细胞肺癌接受4Gy/次、总剂量60Gy的大分割调强放疗显示了有前景的生存,但观察到高级别食管和肺毒性。
研究设计与样本
- 回顾性分析2012-2016年连续42例不可切除III期非小细胞肺癌患者,均接受一线铂类双药诱导化疗后行大分割调强放疗,计划剂量60Gy/15次。
主要发现
- 中位随访46个月(95%CI 41-59),中位总生存47个月(95%CI 31至未达到)。
- 1、2、3、5年总生存率分别为81%、69%、64%、32%;无进展生存率分别为58%、35%、25%、25%。
- 孤立性局部区域复发见于12%(n=5)的患者。
- ≥3级治疗相关肺毒性发生率为14%(n=6),其中G3为9.5%(n=4),G5为4.8%(n=2)。
- 12%(n=5)患者发生G3放射性食管炎,2%(n=1)发生G4食管毒性。
关键数值与推荐
- 放疗剂量为计划60Gy分15次,每次4Gy。
- ≥3级肺毒性14%(n=6),G3 9.5%(n=4),G5 4.8%(n=2)。
- G3放射性食管炎12%(n=5),G4食管毒性2%(n=1)。
临床怎么用
- 该方案可作为不可切除III期非小细胞肺癌的候选治疗选择,但需警惕高级别肺和食管毒性。
局限性
- 回顾性研究,样本量较小(n=42),结果需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the survival, local and distant control, and toxicity in patients with unresectable locally advanced non-small cell lung cancer treated with radical-intent hypofractionated radiation therapy delivering approximately 60 Gy in 4-Gy fractions. METHODS AND MATERIALS: Consecutive patients with unresectable stage III non-small cell lung cancer (n = 42) who received hypofractionated intensity modulated radiation therapy were retrospectively analyzed (2012-2016). Treatments consisted of first-line platinum-based doublet induction chemotherapy followed by an intended dose of 60 Gy in 15 fractions. RESULTS: During a median follow-up period of 46 months (95% confidence interval, 41-59) the median overall survival was 47 months (95% confidence interval, 31 to not reached). The 1-, 2-, 3-, and 5-year overall survival rates were 81%, 69%, 64%, and 32%, respectively. The 1-, 2-, 3-, and 5-year progression-free survival rates were 58%, 35%, 25%, and 25%, respectively. An isolated locoregional recurrence was seen in 12% of the patients (n = 5). The incidence of grade (G) 3 or higher treatment-related lung toxicity was 14% (n = 6), among which G3 toxicity was 9.5% (n = 4) and G5 toxicity was 4.8% (n = 2). Twelve percent of patients (n = 5) experienced G3 radiation esophagitis, and 2% (n = 1) had G4 esophageal toxicity. CONCLUSIONS: Patients with unresectable locally advanced non-small cell lung cancer treated with hypofractionated intensity modulated radiation therapy in doses up to 60 Gy at 4 Gy per fraction had promising survival, although high-grade esophageal and lung toxicities were seen. Our findings deserve further evaluation in prospective studies.
引用
- Kong C, Zhu X, Shi M, et al. Survival and Toxicity of Hypofractionated Intensity Modulated Radiation Therapy in 4 Gy Fractions for Unresectable Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 32275994. doi:10.1016/j.ijrobp.2020.03.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。